

# Accelerating global access to our investigational oral antiviral COVID-19 medicine



We have been committed to providing timely access to our investigational oral antiviral COVID-19 medicine through our comprehensive approach, which includes:

- ✓ Implementing a tiered-pricing approach based on World Bank country income criteria
- ✓ Entering supply agreements with governments
- ✓ Granting voluntary licenses to established Indian generic manufacturers and the Medicines Patent Pool to facilitate availability of generic versions of our medicine to more than 100 low- and middle-income countries
- ✓ Entering an agreement with UNICEF to allocate up to 3 million courses of therapy to low- and middle-income countries




## Accelerating manufacturing

We worked to build capacity quickly — before knowing the data — to produce millions of courses of treatment.





## Advance purchase and supply agreements

As of May 2022, we have entered into advance purchase and supply agreements for our investigational oral antiviral COVID-19 medicine with governments of more than 30 markets worldwide, and are in discussions with additional governments.



## Our purchase agreement with the U.S. government

We entered into an advance purchase agreement with the U.S. government under which the company has supplied approximately 3.1 million courses of our investigational oral antiviral medicine.



## Our pricing approach

We are working through a multi-faceted strategy that includes tiered pricing based on World Bank country income criteria to reflect countries' relative ability to finance their health response to the pandemic.



## Agreements to facilitate access

We are proud of our voluntary licensing agreements with multiple Indian generic companies and our agreement with the Medicines Patent Pool to accelerate availability of our investigational oral antiviral COVID-19 medicine in more than 100 low- and middle-income countries following approvals or emergency authorization by local regulatory agencies.

To supplement the supply from licensed generic manufacturers, Merck has entered an agreement with UNICEF to allocate up to 3 million courses of therapy to low- and middle-income countries.

Merck has also committed up to 3 million patient courses available to USAID at Merck's best access price to increase access in low- and middle-income countries.

**>100** low- & middle-income countries



## Product donations

Merck has committed to donating 100,000 courses of therapy to Direct Relief, a global humanitarian aid organization, for distribution to refugees in low- and middle-income countries.

Our goal is to accelerate equitable access to our investigational oral antiviral COVID-19 medicine for patients no matter where they live.

